ACADIA Pharmaceuticals
1993
FOUNDED
PUBLIC
STATUS
401-500
EMPLOYEES
ACAD
STOCK SYMBOL
$40.43
SHARE PRICE
(As of Monday Closing)
Description
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 3611 Valley Centre Drive
- Suite 300
- San Diego, CA 92130
- United States
+1 (858) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore ACADIA Pharmaceuticals’s full profile, request a free trial.
ACADIA Pharmaceuticals Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $21.04 - $53.70 | $6.23B | $39.34 | -$1.76 | 1.59M | 154M |
ACADIA Pharmaceuticals Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 5,088,048 | 2,109,129 | 3,373,207 | 2,904,064 |
| Revenue | 300,321 | 223,807 | 124,901 | 17,331 |
| EBITDA | (253,875) | (246,279) | (289,697) | (270,987) |
| Net Income | (247,715) | (245,192) | (289,403) | (271,393) |
| Total Assets | 765,586 | 540,202 | 384,506 | 561,153 |
| Total Debt | 10,268 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
ACADIA Pharmaceuticals Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore ACADIA Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookACADIA Pharmaceuticals Competitors (51)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| SAGE Therapeutics | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 00000000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Waltham, MA | 00 | 00000 | 00000000 | 00000 |
| 00000000 000000000 | Formerly VC-backed | Coral Gables, FL | 00 | 000.00 | 00000000 | 000.00 |
| 000000000 00000000 | Corporation | Pasadena, CA | 000 | 00.000 | 0000 | |
| 00 0000000 | Formerly Accelerator/Incubator backed | Paris, France | 000 | 000.00 | 000000000 | 000.00 |
ACADIA Pharmaceuticals Executive Team (17)
10 Former Executives
You’re viewing 5 of 17 executives. Get the full list »ACADIA Pharmaceuticals Board Members (13)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Daniel Soland | ACADIA Pharmaceuticals | Board Member | 000 0000 | |
| Edmund Harrigan MD | Self | Board Member | 000 0000 | |
| Julian Baker | Self | Board Member | 000 0000 | |
| Laura Brege | ACADIA Pharmaceuticals | Board Member | 000 0000 | |
| Stephen Biggar Ph.D | Self | Chairman & Board Member | 000 0000 |
7 Former Board Members
You’re viewing 5 of 13 board members. Get the full list »